NCT02986373View on ClinicalTrials.gov

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

PHASE2CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

July 8, 2018

Study Completion Date

July 30, 2018

Conditions
Psoriatic Arthritis
Interventions
BIOLOGICAL

risankizumab

Risankizumab administered by subcutaneous injection.

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY